Creating New β-Globin-Expressing Lentiviral Vectors by High-Resolution Mapping of Locus Control Region Enhancer Sequences

Molecular Therapy: Methods & Clinical Development

Mildred J. Unti¹  Feiyang Ma²  Yukio Nakamura³  Ryan L. Wong³  Matteo Pellegrini³  Curtis Tam³  Bamidele Aleshe³  Richard A. Morgan⁴  Paul George Ayoub⁵  Donald B. Kohn⁵  Lindsay Lathrop⁵  Ryo Kurita⁵  Shantha Senadheera⁵  Roger P. Hollis⁵  Devin Brown⁶ 

[1] Corresponding author: Richard A. Morgan, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA.;Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA;Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA;Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA;;Department of Microbiology, Immunology &Molecular Biology Institute Interdepartmental Doctoral Program, University of California, Los Angeles, Los Angeles, CA 90095, USA;

关键词: hemoglobin;    SCD;    sickle cell disease;    MPRA;    Massively Parrallel Reporter Assay;    Shuffling;   

DOI  :  

来源: DOAJ

【 摘 要 】

Hematopoietic stem cell gene therapy is a promising approach for treating disorders of the hematopoietic system. Identifying combinations of cis-regulatory elements that do not impede packaging or transduction efficiency when included in lentiviral vectors has proven challenging. In this study, we deploy LV-MPRA (lentiviral vector-based, massively parallel reporter assay), an approach that simultaneously analyzes thousands of synthetic DNA fragments in parallel to identify sequence-intrinsic and lineage-specific enhancer function at near-base-pair resolution. We demonstrate the power of LV-MPRA in elucidating the boundaries of previously unknown intrinsic enhancer sequences of the human β-globin locus control region. Our approach facilitated the rapid assembly of novel therapeutic βAS3-globin lentiviral vectors harboring strong lineage-specific recombinant control elements capable of correcting a mouse model of sickle cell disease. LV-MPRA can be used to map any genomic locus for enhancer activity and facilitates the rapid development of therapeutic vectors for treating disorders of the hematopoietic system or other specific tissues and cell types.

【 授权许可】

Unknown